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Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of dominant and sporadic Parkinson’s
disease (PD), a common neurodegenerative disorder. Yeast-two-hybrid screening using human LRRK2 kinase
domain as bait identified microtubule associated protein 1B (MAP1B) as a LRRK2 interactor. The interacting domains
were LRRK2 kinase and the light chain portion of MAP1B (LC1). LRRK2 + LC1 interaction resulted in LRRK2 kinase
inhibition. LRRK2 mutants (R1441C, G2019S and I2020T) exhibited decreased endogenous LC1 expression and its
co-expression with LC1 rescued LRRK2 mutant-mediated toxicity. This study presented the first data on the effects
of LRRK2 + LC1 interaction and also suggested that LCI possibly rescued LRRK2 mutant-induced cytotoxicity by
inhibiting LRRK2 kinase activity. Compounds that upregulate LC1 expression may therefore hold therapeutic
potential for LRRK2-linked diseases.
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Parkinson’s disease (PD), a neurodegenerative disorder,
has been estimated to afflict six million people world-
wide [1,2] and mutations in the leucine-rich repeat kin-
ase 2 (LRRK2) gene is the most common cause of
dominant and sporadic PD [3,4]. Common pathogenic
LRRK2 mutations like R1441C/G, Y1699C, G2019S and
I2020T reside within the Roc-COR-kinase domains and
are associated with increased kinase activity, which is in
turn linked to increased neurotoxicity [5,6]. Though the
enzymatic functions of LRRK2 have been extensively
studied, its physiological mechanism remains unknown.
Hence, recent LRRK2 research focused on the identifica-
tion of LRRK2 interactors/substrates as they will provide
vital pathophysiologic clues.
Recently, LRRK2 was reported to phosphorylate and
negatively regulate Futsch, the fly homolog of microtubule-
associated protein 1B (MAP1B), at the pre-synapse [7].
The MAP1B complex comprises of the heavy chain (HC)
and light chain (LC1) subunits [8]. LC1 has been re-
ported to dimerize or oligomerize [9] and its overexpres-
sion can lead to endoplasmic reticulum stress-induced
apoptosis [10].* Correspondence: sharon.chan@live.com.sg
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LRRK2 kinase domain as bait, LC1 was identified as a
LRRK2 interactor. This study presented the first data on
the effects of LRRK2 and LC1 interaction and also sug-
gested that LCI possibly rescued LRRK2 mutant-induced
cytotoxicity by inhibiting LRRK2 kinase activity.
Materials and methods
Immunocytochemistry
SKNSH cells were fixed in 4% paraformaldehyde and
probed with LRRK2 (Novus) and LC1 (Santa Cruz) pri-
mary antibodies (1:200) at 4°C overnight. Subsequently,
secondary antibodies (Invitrogen), Alexa488 (LRRK2)
and Alexa546 (LC1), were added to cells and incubated
at room temperature for one hour. Cells were mounted
with DAPI and immunofluorescence was visualised.
Kinase assays
LRRK2 kinase assay was carried out using the ADP
Hunter assay (BMG labtech, Offenburg, Germany), trun-
cated LRRK2 protein (Invitrogen), 10 mM ATP (Sigma-
Aldrich) and purified LC1-GST. Reagents were mixed and
incubated at room temperature for two hours; reaction
was stopped by adding sample loading dye and boiling
for five minutes. Primary antibodies, phospho-threonine
(Cell Signaling) and phospho-serine (Millipore) were
used at the concentration 1:1000.td. This is an Open Access article distributed under the terms of the Creative
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Figure 1 The interaction and phosphorylation of LRRK2 and
LC1. (A) Cellular co-localisation of endogenous LRRK2 and MAP1B
(LC1). SKNSH cells were labelled with LRRK2 (green) and LC1 (red)
antibodies and signals were detected by immunofluorescence.
Detailed figure in Additional file 1. (B) LRRK2 kinase assay. The LRRK2
wild-typed (WT) kinase interacted and phosphorylated the LC1
domain unlike the LRRK2 kinase-dead protein. (C) Western blotting
of LRRK2 and LC1 proteins after a kinase assay. Both LRRK2 and LC1
proteins were probed for phospho-threonine and phospho-serine
signals respectively.
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Human LRRK2 WT, G2019S and I2020T were cloned
into pEGFP-N1 vectors and LC1 was cloned into
pGEX5X1 vector. R1441C plasmid was cloned by Mark
Cookson [11] and obtained from Addgene (plasmid
25046). Human neuroblastoma cells (SKNSH; ATCC)
was transfected using Turbofect (Thermo Scientific) and
incubated for 48 hours before cell lysates were collected
and resolved by SDS-PAGE. Primary antibodies, LC1
(Santa Cruz) and β-actin (Sigma-Aldrich), were used at
the concentration 1:1000 and all secondary antibodies
(Santa Cruz) were used at the concentration 1:2000. Re-
sultant western blot bands were quantified using the
NIH ImageJ software [12] and tabulated in a bar graph.
Functional assays
Cell viability assays utilised Methylthiazolyldiphenyl-
tetrazolium bromide (MTT, Sigma-Aldrich); MTT
(0.5 mg/mL) was added to transfected cells and incu-
bated at 37°C for three hours before resultant formazan
was solubilised in DMSO and quantified. Caspase-Glo 3/7
luminescent apoptosis assay (Promega, Wisconsin, USA)
was carried out according to manufacturer’s instructions.
Statistical analysis was carried out using the Student’s
t-test.
Results
Yeast-two-hybrid screening was performed as previously
mentioned [13]. Briefly, a human brain cDNA library
was screened using the human LRRK2 kinase domain as
bait. Three out of 54 surviving clones in highly stringent
growth media contained open reading frames that
shared 99% homology to LC1 (accession number
NM_005909; data not shown). The interaction between
LRRK2 and LC1 was validated by their subcellular
co-localisation in SKNSH using immunofluorescence
(Figure 1A and Additional file 1: Figure S1). LRRK2 +
LC1 interaction was further supported when purified
LC1-GST protein successfully pulled down the LRRK2
kinase domain that was overexpressed in SKNSH (Add-
itional file 1: Figure S2). Consequently, a LRRK2 kinase
assay was carried out to reveal that LC1 was phosphory-
lated by LRRK2 at its serine residues but not threonine.
Additionally, LRRK2 + LC1 interaction appeared to in-
hibit LRRK2 autophosphorylation at its threonine sites
(Figures 1B & C). It should be noted that the phospho-
threonine signals were much stronger than the phospho-
serine signals via western blot detection.
To investigate the effect of LRRK2 mutations on en-
dogenous LC1 expression, wild-typed LRRK2 (WT) or
its mutants (G2019S, R1441C, I2020T) were transiently
expressed in SKNSH. Cell lysates were analysed by SDS-
PAGE to reveal a decrease in endogenous LC1 expres-
sion with LRRK2 mutants compared to WT (Figure 2).As LRRK2 mutants have been shown to be more neuro-
toxic than WT [5], the effect of LC1 co-expression on
LRRK2-mediated cytotoxicity was investigated. SKNSH
transfected with LRRK2 alone or co-transfected with
LRRK2 + LC1 was assayed for their cell viability using
MTT. The co-expression of LRRK2 + LC1 appeared to
Figure 2 Endogenous LC1 protein expression in SKNSH cells.
Cells were transiently expressing LRRK2-WT or one of its mutants.
After 48 hours, cell lysates were analysed by western blotting and
beta actin was used as a loading control. The signal intensity of the
western blot bands was corrected for beta actin and quantified





















Figure 3 Functional assays of LRRK2 and LC1 interaction.
(A) MTT assay of SKNSH transiently expressing LRRK2-WT or its
mutants alone (black columns) or co-expression with LC1 (grey
columns). Experiment was performed in triplicates and repeated
three times. Data represent mean values with standard error bars.
(B) Apoptosis assay of SKNSH transiently expressing LRRK2 or its
mutants alone (black columns) or co-expression with LC1 (grey
columns). Experiment was carried out with six replicates and data in
the bar graph represent mean values with standard error bars.
Statistical significance was determined using Student’s t-test and
*p < 0.05, **p < 0.01 and ***p < 0.001.
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cytotoxicity (Figure 3A). An apoptosis assay was next car-
ried out to determine if this LC1-related rescue is linked
to apoptosis. The overexpression of LC1 in control cells
appeared to increase the levels of apoptosis, whereas the
co-expression of LRRK2 appeared to neutralize or de-
crease the extent of apoptosis (Figure 3B).Discussion
MAP1B was identified as a LRRK2 interactor through
yeast-two-hybrid screening using human LRRK2 kinase
domain as bait; the interacting domains were narrowed
down to the LRRK2 kinase and LC1. The MAP1B com-
plex comprises of the HC and LC1 subunits. LC1 has
microtubule stabilizing activity and the HC has been re-
ported to act as the regulatory subunit of the MAP1B
complex to control LC1 activity [9]. LC1 appeared to in-
hibit LRRK2 kinase activity and a decrease in endogen-
ous LC1 expression was observed in LRRK2 mutants
that exhibited increased toxicity. Subsequent functional
assays showed that transient LRRK2 mutant expression
caused acute toxicity through apoptosis, which could be
rescued by the co-expression of LC1. LRRK2 kinase
activity is central to its pathogenicity as LRRK2 kinase-
dead mutants are not toxic [11]. These observations sug-
gest that LCI is an important mediator of LRRK2mutant-related toxicity and this is possibly linked to
LRRK2 kinase inhibition.
The interaction between LRRK2 and LC1 is supported
by an earlier report which showed that LRRK2 phos-
phorylates Futsch, a fly homolog of MAP1B [7]. LRRK2
was reported to negatively regulate the presynaptic func-
tion of Futsch in controlling microtubule dynamics [7]
and this study showed that LRRK2 kinase phosphory-
lated LC1 at serine residues while concurrently inhibit-
ing LRRK2 autophosphorylation at threonine residues.
Similarly, as the co-expression of Futsch was able to res-
cue synaptic morphology defects induced by human
LRRK2 overexpression [7], this report demonstrated that
the co-expression of LC1 was able to neutralise or res-
cue the observed apoptotic effect with wild-typed
LRRK2 and mutant LRRK2 respectively.
In conclusion, this study validated MAP1B as a LRRK2
interactor and specified LC1 as its interacting domain. It
showed concurrent LRRK2 kinase inhibition while phos-
phorylating LC1 and the effect of this interaction pos-
sibly neutralised LRRK2 mutant-mediated cytotoxicity
by inhibiting its kinase activity. This provided additional
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the regulation of LRRK2+ LC1 interaction is a potential
avenue for the development of LRRK2 therapeutics.
Additional file
Additional file 1: Figure S1. Cellular co-localisation of endogenous
LRRK2 and MAP1B-LC1 (LC1). Endogenous LRRK2 (green) and LC1 (red) in
SKNSH were labelled with antibodies and signals were detected using
immunofluorescence. Nucleus was stained with DAPI (blue) and figures
were merged to observe co-localisation. Figure S2. LC1-GST pulldown
assay. Purified LC1-GST protein and GST protein were used to pull down
LRRK2 kinase myc from LRRK2 kinase myc-transfected SKNSH lysate.
Purified protein was added to SKNSH lysate and incubated at 4°C for
2 hours before detecting with anti-myc antibody.
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